Business Wire

Technology Innovation Institute’s Secure Systems Research Centre in Abu Dhabi Announces Launch of First Motion Capture Facility Outside United States

8.9.2021 15:29:00 EEST | Business Wire | Press release

Share

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) is pioneering a first-in-the-region Motion Capture (MOCAP) facility. Outside of the United States, SSRC’s unique MOCAP facility at its Masdar City premises, will enable the testing of Unmanned Aerial Systems (UAS) or drones in an augmented reality (AR) or mixed reality environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005700/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr Shreekant (Ticky) Thakkar, Chief Researcher, Secure Systems Research Centre, Technology Innovation Institute (Photo: AETOSWire)

The MOCAP facility will allow SSRC to simulate flying through the city of Abu Dhabi and enable high-precision ground truth to conduct sophisticated experiments as well as virtual, augmented and mixed reality testing. The ability to simulate virtual camera images and sensors facilitates testing in environments that are too large, too dangerous, or too time consuming to construct in reality.

The high-quality motion capture system proposed for Abu Dhabi will be able to conduct passive or active tracking and enhance the communication, navigation, command, and control capabilities achieved to date. SSRC is shaping this facility in line with its ongoing collaboration with US-based Purdue University that holds the distinction for the largest indoor motion capture facility in the world.

Speaking on the breakthrough facility that will allow the modelling and operation of a cloud-based secure autonomous system of drones - as opposed to just autonomous drones - in this environment, Dr Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “This is a start – an ambitious one – and we are confident we will be able to arrive at technologies that could limit malicious cyber-attacks as our reliance on drones continues to increase every day. They are integral to life today – from delivering valuable organs at a hospital to conducting surveillance of high-security zones, or dispersing seeds over a field or even completing grocery deliveries.

“This unique testing facility will be leveraged by various lab groups and allow us to conduct experiments on a broad range of Unmanned Aerial Systems of various sizes while the state-of-the-art high-resolution cameras track small objects in the surrounding environment. Our aim at SSRC is to develop breakthrough security solutions to safeguard systems that may be vulnerable, such as unsecure drone systems which may pose various threats to organisational or even individual privacy and safety. Therefore, it’s essential to make drone platforms more resilient and secure.”

On the construction of the new facility, James Goppert, Managing Director of the Purdue UAS Research and Test Facility said: “Autonomous drones are already playing a key part in package delivery and infrastructure inspection. As smart cities evolve, it will be critical to ensure the safe operation of drones in an urban setting. This facility is particularly suited to the task of bringing algorithms for the security of drones from simulation to real world application by allowing a gradual transition of scenario elements from pure simulation, to virtual, to real-world.”

The testing facility will be used by both the Secure Systems Research Centre and TII’s Autonomous Robotics Research Centre to carry out experiments on a range of vehicles. As a shared space, the Motion Capture facility can accommodate micro UAS weighing less than 10 g to large UAS that are as heavy as 1,000 kg and factor in different types of UAS from multirotor to helicopters to vertical takeoff and landing vehicles (VTOLs) to fixed wing craft.

For information on Technology Innovation Institute, visit www.tii.ae

For information on Secure Systems Research Centre, visit https://securesystems.tii.ae/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Hanz Valbuena
comms@atrc.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release

Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto

ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo

NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots

Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est

Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release

Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye